Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization of TNBC are encouraging the development of novel drugs and therapeutic combinations for its therapeutic management. In the present review, we will provide an overview of the currently available standard therapies and new emerging therapeutic strategies against TNBC, highlighting the promises that newly developed small molecules, repositioned drugs, and combination therapies have of improving treatment efficacy against these tumors.
Masci, D., Naro, C., Puxeddu, M., Urbani, A., Sette, C., La Regina, G., Silvestri, R., Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment, <<MOLECULES>>, 2023; 28 (22): 1-48. [doi:10.3390/molecules28227513] [https://hdl.handle.net/10807/267135]
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
Masci, DomizianaPrimo
;Naro, Chiara;Urbani, Andrea;Sette, Claudio;La Regina, Giuseppe;
2023
Abstract
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization of TNBC are encouraging the development of novel drugs and therapeutic combinations for its therapeutic management. In the present review, we will provide an overview of the currently available standard therapies and new emerging therapeutic strategies against TNBC, highlighting the promises that newly developed small molecules, repositioned drugs, and combination therapies have of improving treatment efficacy against these tumors.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
